Brief: Marinus Pharmaceuticals says Cash Runway Now Expected Into Q4 Of 2024

Marinus Pharmaceuticals

19/09/2023 13:19

Sept 19 (Reuters) - Marinus Pharmaceuticals Inc
 MRNS.O :
    * MARINUS PHARMACEUTICALS INC- CASH RUNWAY NOW EXPECTED INTO
Q4 OF
2024
    * MARINUS: RAISE TRIAL ENROLLMENT TRENDS HAVE RETURNED TO
ANTICIPATED LEVELS
    * MARINUS PHARMACEUTICALS INC- PROJECTED CASH, CASH
EQUIVALENTS &
SHORT-TERM INVESTMENTS OF BETWEEN $170 MILLION AND $175 MILLION
AS OF SEPT 30, 2023
    * MARINUS: ON TRACK FOR TOPLINE DATA ROM RAISE TRIAL IN Q1
2024,
ASSUMING PRE-DEFINED STOPPING CRITERIA FOR INTERIM ANALYSIS MET
    * MARINUS- CONTINUED EXECUTION OF COMMERCIAL LAUNCH OF
ZTALMY WITH
ESTIMATED NET PRODUCT REVENUE OF BETWEEN $5 AND $5.2 MILLION FOR
Q3 2023
    * MARINUS PHARMACEUTICALS INC- ON TRACK TO MEET FULL YEAR
2023
EXPECTED ZTALMY NET PRODUCT REVENUES OF BETWEEN $17 AND $18.5
MILLION

Source text for Eikon:  ID:nBwbyy1bha 
Further company coverage:  MRNS.O 

 ((Reuters.Briefs@thomsonreuters.com))